Lantheus (LNTH) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 93.2% versus a loss of 83.4%. Lantheus is the larger company by market cap ($6.54 billion vs $215.1 million), about 30.4 times the size. On valuation, Lantheus trades at a lower trailing P/E (24.3x vs 32.7x for Anbio Biotechnology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | NNNN |
|---|---|---|
| Share price | $100.18 | $4.90 |
| Market cap | $6.54B | $215.07M |
| 1-day change | +0.23% | 0.00% |
| YTD return | +50.53% | -83.70% |
| 1-year return | +93.25% | -83.37% |
| 5-year return | +330.70% | — |
| P/E ratio (TTM) | 24.26 | 32.67 |
| Forward P/E | 15.71 | — |
| EPS (TTM) | $4.13 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | — |
| Revenue growth (YoY) | +0.50% | — |
| Net income (latest FY) | $233.56M | — |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | — |
| Net margin | 15.15% | — |
| 52-week high | $111.86 | $44.73 |
| 52-week low | $50.16 | $4.66 |
| Distance from 52-week high | -10.44% | -89.05% |
| Analyst consensus | none | — |
| Avg. price target upside | +7.55% | — |
| Average volume | 1.34M | 148.96K |
| Shares outstanding | 65.30M | 43.89M |
| Employees | 1,193 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 30.4 times larger than Anbio Biotechnology by market value ($6.54B vs $215.07M).
- LNTH has outperformed NNNN by 176.6 percentage points over the past year.
- Anbio Biotechnology trades at a higher earnings multiple (32.7x vs 24.3x trailing P/E).
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
LNTH vs NNNN FAQ
Which is bigger, Lantheus or Anbio Biotechnology?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $215.07M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, LNTH or NNNN?
LNTH returned +93.25% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, LNTH or NNNN?
LNTH has the lower trailing P/E at 24.3, versus 32.7 for NNNN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Lantheus and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.